| FBLTX | VEDTX | FBLTX / VEDTX | |
| Total Expense Ratio | 0.03 | 0.05 | 60% |
| Annual Report Gross Expense Ratio | 0.05 | 0.05 | 100% |
| Fund Existence | 11 years | 19 years | - |
| Gain YTD | -4.315 | -6.264 | 69% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 0 | 5000000 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 12.8B | 4.14B | 310% |
| Annual Yield % from dividends | 4.39 | 5.41 | 81% |
| Returns for 1 year | -4.73 | -7.96 | 59% |
| Returns for 3 years | -0.56 | -8.79 | 6% |
| Returns for 5 years | -35.18 | -49.26 | 71% |
| Returns for 10 years | -23.58 | -38.43 | 61% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| FLCKX | 44.21 | 0.53 | +1.21% |
| Fidelity Leveraged Company Stock K | |||
| TBCIX | 215.21 | 1.28 | +0.60% |
| T. Rowe Price Blue Chip Growth I | |||
| GRGTX | 55.15 | -0.14 | -0.25% |
| Goldman Sachs Equity Income Inv | |||
| FIJCX | 91.57 | -0.62 | -0.67% |
| Fidelity Advisor Consumer Staples Z | |||
| RYOIX | 93.54 | -1.10 | -1.16% |
| Rydex Biotechnology Inv | |||